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1. Few studies have evaluated the pharmacokinetics of rapid-acting insulin 
analogues in patients with type 2 diabetes, especially under clinical conditions. The aim 
of this study was to assess both the pharmacokinetics and pharmacodynamics of insulin 
aspart in type 2 diabetic patients who were being treated with the analogue alone. 
2. Meal tolerance tests with and without self-injection of a customary dose of 
insulin aspart (0.05–0.22 U/kg) were conducted in 20 patients in a randomised 
crossover study. 
3. The dose (per body weight) of insulin aspart was significantly correlated with 
both the maximum concentration (r2 = 0.59, P < 0.01) and area under the 
concentration-time curve for insulin aspart (r2 = 0.53, P < 0.01). However, the time to 
maximum concentration (tmax), which varied widely from < 60 min to ≥ 120 min, was 
not associated with either dosage (r2 = 0.02, P = 0.51) or body mass index (r2 = 0.02, 
P = 0.57). Injection of insulin aspart exacerbated delayed hyperinsulinaemia after meal 
loading, mainly in patients with tmax values ≥ 120 min. With regard to 
pharmacodynamics, insulin aspart had favourable effects on postprandial 
hyperglycaemia, hyperglucagonaemia, and hyperlipidaemia. 
4. The tmax for this insulin analogue differed greatly between individuals, and 
delayed hyperinsulinaemia was particularly exacerbated in patients with higher tmax 
values. Identification of the factors contributing to inter-individual variation in the 
absorption lag time is essential for improving its efficacy and safety. 
Key words: insulin aspart, rapid-acting insulin analogues, delayed hyperinsulinaemia, 
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The elevation of postprandial plasma glucose levels, which occurs due to the loss 
of first-phase insulin secretion, decreased insulin sensitivity, and consequent defective 
suppression of hepatic glucose output after meals, begins prior to the onset of type 2 
diabetes.1,2 Therefore, postprandial hyperglycaemia is common in patients with type 2 
diabetes, even when overall glycaemic control, as assessed by measuring glycosylated 
haemoglobin levels, appears to be adequate.3 Because post-challenge hyperglycaemia is 
known to be an independent risk factor for cardiovascular disease and all-cause 
mortality,4,5 various agents that target postprandial plasma glucose, including 
rapid-acting insulin analogues, are now used clinically in the treatment of type 2 
diabetes. Of note, mealtime dosing of a rapid-acting insulin analogue, without basal 
insulin or any other medications, improved both postprandial and early morning fasting 
plasma glucose levels in approximately one-half of 40 Japanese patients with type 2 
diabetes.6 
Insulin aspart is a rapid-acting insulin analogue in which proline 28 in the B chain 
has been replaced by aspartic acid.7 Several studies have investigated the 
pharmacokinetics of insulin aspart and have compared the results to those for regular 
insulin7-14 or other rapid-acting insulin analogues.15-18 However, most of these studies 
were conducted in healthy subjects7-10,13,18 or patients with type 1 diabetes.12,16,17 In 
addition, studies in patients with type 2 diabetes used a dose of insulin aspart that was 
weight-adjusted, but not clinically appropriate for each patient.11,14,15 Recently, 
Gagnon-Auger et al.19 used a euglycaemic clamp to show that the pharmacokinetics of 
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insulin lispro, another rapid-acting insulin analogue, differ between healthy subjects and 
patients with type 2 diabetes, and that the time to maximum concentration (tmax) is 
dose-dependently increased in diabetic patients. Therefore, the pharmacokinetics of 
insulin aspart should be assessed in patients with type 2 diabetes, especially under 
clinical conditions. To address the issue, we determined the pharmacokinetics of a 
customary dose of insulin aspart administered immediately before eating in type 2 
diabetic patients receiving insulin aspart monotherapy. Another trial with a randomised 
crossover design was performed without insulin aspart. By comparing the 
concentration-time profiles of endogenous insulin, glucose, glucagon, triglycerides, and 
remnant-like particle (RLP)-cholesterol in these trials, we further evaluated the 






This study was conducted between February and June 2007. A total of 20 Japanese 
patients with type 2 diabetes were recruited from the outpatient clinic at Kanazawa 
University Hospital (Kanazawa, Japan) based on the following inclusion criteria: 1) 
treatment with insulin aspart monotherapy, i.e., dosing of pure insulin aspart at each 
mealtime without combined administration of any oral antidiabetic agent or other 
insulin preparation6 for at least 3 months; 2) relatively good and stable glycaemic 
control, as defined by two consecutive haemoglobin A1c measurements of < 7.4% and a 
difference between measurements of < 0.5%; and 3) all chronic diseases other than type 
2 diabetes, such as hypertension and dyslipidaemia, being stable. For insulin aspart 
monotherapy, the breakfast, lunch, and dinner doses of insulin aspart were adjusted in 
an attempt to achieve plasma glucose levels of 4.4–6.7 mmol/l before lunch, dinner, and 
bedtime, respectively. Patients with anaemia, acute diseases, existing malignancy, or 
severe renal or hepatic dysfunction, as well as women of childbearing potential, were 
excluded. Five healthy, non-diabetic Japanese individuals were recruited as controls. 
The characteristics of the subjects are shown in Table 1. Eight patients with diabetes 
had been treated with one or more antihypertensive medications: angiotensin receptor 
blocker (n = 5), calcium channel blocker (n = 5), diuretic (n = 2), beta-blocker (n = 1), 
or angiotensin-converting enzyme inhibitor (n = 1). Six patients received continuous 
treatment with a lipid-lowering agent: statin (n = 5) or fibrate (n = 1). 
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This study was approved by the ethics committee of Kanazawa University 
(Kanazawa, Japan) and was conducted in accordance with the Declaration of Helsinki. 
All subjects provided written informed consent before participating in the study. 
 
Study design 
In the morning following an overnight fast, participants consumed a test meal 
developed by a working group of the Japan Diabetes Society (460 kcal; protein, 18.0 g; 
fat, 18.0 g; carbohydrate, 56.5 g; E460F18, Q. P. Corp., Tokyo, Japan), along with 100 
ml of water, within 15 min.20 The participants were asked to remain seated and blood 
samples were obtained immediately before and at 30, 60, 120, and 180 min after 
ingestion of the test meal. In diabetic patients, tests with and without subcutaneous 
administration of insulin aspart (NovoRapid; Novo Nordisk Pharma Ltd., Tokyo) just 
before meal loading were conducted according to a randomised crossover schedule with 
an interval ranging from 7 to 56 days (mean, 20 days). Insulin aspart was administered 
in the abdomen at a customary dose for breakfast time (range, 3–12 U; mean, 7.0 U). 
The insulin injection site and technique were checked by at least one doctor. All 
participants completed the study, and the medications taken by the diabetic patients did 
not change throughout the study period. 
 
Assays 
Serum concentrations of total insulin (i.e., endogenous insulin plus exogenous 
insulin aspart) were measured using an E-test TOSOH II IRI immunoassay kit (Tosoh 
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Corp., Shunan, Japan), because the cross-reactivity of the insulin monoclonal antibody 
with insulin aspart is reported to be approximately 100%.21 In addition, endogenous 
insulin concentrations were assayed using another enzyme immunoassay kit 
(LUMIPULSE Presto Insulin; Fujirebio Inc., Tokyo) because we found that the reagent 
does not cross-react with insulin aspart (Supplemental Fig. 1). The circulating insulin 
aspart concentration was calculated by subtracting the endogenous insulin concentration 
from the total insulin concentration. Plasma glucagon and serum RLP-C concentrations 
were determined using a Daiichi II radioimmunoassay kit (TFB Inc., Tokyo) and a 
JIMRO II assay kit (Otsuka Pharmaceutical Co., Tokyo), respectively. The other 
variables were measured by standard methods. The inter-assay coefficients of variation 
were all ≤ 15%. Haemoglobin A1c (National Glycohemoglobin Standardization 
Program) values were estimated using the following formula:22 
Haemoglobin A1c (National Glycohemoglobin Standardization Program) (%) 
= haemoglobin A1c (Japan Diabetes Society) (%) + 0.4%  
 
Data analysis 
Metabolic parameter profiles during meal tolerance tests were characterised by 
recording the values for maximum concentration (Cmax), tmax, and the area under the 
concentration-time curve between 0 and 180 min after meal loading (AUC0-180). Cmax 
and tmax were determined directly from the observed data. AUC0-180 was calculated 
according to the trapezoidal rule. 
Raw or log-transformed data were analysed using a Student’s t-test or by an 
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analysis of variance (ANOVA) or Kruskal-Wallis test followed by Bonferroni post-hoc 
tests. Associations between variables were assessed using Spearman’s rank correlation 
coefficient. The values are presented as means ± standard deviation (SD) unless 
otherwise indicated. Two-sided P values of < 0.05 were considered statistically 
significant. All calculations were performed using SPSS for Windows version 11 (SPSS 
Japan, Tokyo). Graphic representations and curve fitting were performed using 




In non-diabetic healthy subjects, the concentration of endogenous insulin rapidly 
and transiently increased after ingestion of the test meal, with a mean tmax value of 36 
min (Fig. 1 and Table 2). The tmax value for endogenous insulin was significantly higher 
in patients with type 2 diabetes (mean, 84 min; Table 2), and the serum insulin 
concentration at 180 min after meal loading was higher in diabetic patients than in 
control subjects (121 ± 87 vs. 39 ± 18 pmol/L; P < 0.05; Fig. 1). Thus, diabetic patients 
exhibited delayed mild hyperinsulinaemia after meal loading. 
The serum concentration of insulin aspart increased after subcutaneous 
administration of a therapeutic dose (0.11 ± 0.04 U/kg), with a mean tmax of 63 min. The 
values of Cmax and AUC0-180 for insulin aspart were 391 ± 282 pmol/L and 42.8 ± 31.9 
nmol·min/L, respectively. Consequently, the tmax for total insulin decreased slightly, and 
total insulin concentrations (Cmax and AUC0-180) in the trial involving insulin aspart were 
twice as high as those in the trial not involving insulin aspart (Table 2). Moreover, 
insulin aspart administration reduced the AUC0-180 for endogenous insulin by 29% 
(P < 0.01). 
As expected, the dose (per body weight) of insulin aspart was significantly 
correlated with both Cmax (Fig. 2a) and AUC0-180 (Fig. 2b). However, the dosage did not 
affect the tmax for insulin aspart (Fig. 2c). In contrast, the tmax for insulin lispro has been 
reported to increase dose-dependently.19 In addition, body mass index did not correlate 
with the tmax for insulin aspart (Fig. 2d). These results suggest that the tmax for insulin 




The total insulin concentration at 180 min after meal loading tended to remain 
higher in the trial involving insulin aspart than in the one not involving insulin aspart 
(170 ± 128 vs. 121 ± 87 pmol/L; P = 0.11). Moreover, the tmax for insulin aspart was 
significantly correlated with the total insulin concentration at 180 min (Fig. 2e). 
Collectively, these results indicate that the clinical use of insulin aspart exacerbates 
delayed hyperinsulinaemia in a subset of patients with type 2 diabetes, notably those 
with higher tmax values. 
Concentration-time profiles for circulating glucose, glucagon, triglycerides, and 
RLP-cholesterol after ingestion of the test meal are shown in Fig. 3. As shown in Table 
2, the administration of insulin aspart significantly attenuated postprandial 
hyperglycaemia (Cmax and AUC0-180 for glucose) (P < 0.01). The plasma glucose level at 
180 min after meal loading was lower than that before meal loading (6.1 ± 1.7 vs. 
7.7 ± 1.0 mmol/L; P < 0.01). Although the plasma glucose level fell to less than 3.9 
mmol/L in two patients, symptoms of hypoglycaemia were not observed in any patient. 
In addition, insulin aspart significantly increased the tmax for glucagon (Table 2). 
Compared with the respective values in healthy subjects, postprandial concentrations of 
triglycerides and RLP-cholesterol (Cmax and AUC0-180) were significantly higher and 
tended to be higher, respectively, in diabetic patients (Table 2). However, the abnormal 





Previous studies have demonstrated that insulin aspart has a faster onset and 
shorter duration of action than regular human insulin.7-14 In healthy subjects, the mean 
tmax for insulin aspart has been reported to be 31–33 min (at a dose of 0.025 U/kg),10,18 
39 min (0.05 U/kg),10 52 min (0.1 U/kg),9 and 52–70 min (0.2 U/kg),7,8 suggesting that 
the tmax for insulin aspart increases in a dose-dependent manner. In the present study, 
however, a dose-dependent increase in tmax was not observed for doses of insulin aspart 
in the range 0.05 to 0.22 U/kg (Fig. 2c). The value of tmax differed widely between 
individuals and was 120 min or higher in 20% of patients (4 of 20). It is known that 
increasing adiposity (i.e., obesity) delays insulin absorption.23 In addition, the 
absorption and hypoglycaemic action of insulin analogues were reported to be delayed 
in obese patients with type 2 diabetes.19 However, no correlation between tmax for 
insulin aspart and body mass index was observed in this study (Fig. 2d). Because body 
mass index does not accurately reflect body fat percentage or subcutaneous fat thickness, 
it remains to be determined whether or not these factors are associated with tmax for 
insulin aspart. Regardless, this study demonstrated for the first time that inter-individual 
differences in the absorption of insulin aspart exist in patients with type 2 diabetes 
under clinical conditions, irrespective of differences in insulin dosage and body mass 
index. 
Multiple factors, including injection site, skin temperature, physical activity, 
smoking, and age, can affect the absorption of exogenous insulin.7,24,25 Injection depth, 
which depends on the injection technique, also affects insulin absorption.26 Additionally, 
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repeated injection of exogenous insulin or one of its analogues (including insulin aspart) 
at the same site may induce lipoatrophy, resulting in erratic absorption.27 In the present 
study, all patients self-injected insulin aspart into their customary abdominal region 
using their own devices. In addition, lifestyle habits such as morning exercise and 
smoking were not restricted. Therefore, various factors may have influenced the value 
of tmax for insulin aspart. On the other hand, these factors appear to have had minimal 
effects on the values of Cmax and AUC0-180, which were clearly dependent on the dosage 
of insulin aspart (Figs 2a and 2b). Interestingly, the reported tmax for insulin aspart at a 
dose of 0.15 U/kg differed between patients with type 1 diabetes (40 min)12 and those 
with type 2 diabetes (70 min),14 whereas the values of both Cmax (493 and 507 pmol/L, 
respectively) and AUC (71.0 and 73.7 nmol·min/L, respectively) were comparable 
between the two patient groups. These observations indicate that factors contributing to 
variation in the value of tmax for insulin aspart need to be identified. However, because 
multiple factors, rather than a single factor, generally affect insulin absorption in a 
patient,24 and because these factors may influence each other,24 it might be difficult to 
identify the most important factor. Therefore, at least at present, it is important to 
remember that the value of tmax for insulin aspart differs between individuals and that 
delayed hyperinsulinaemia is pronounced in some patients. 
Delayed hyperinsulinaemia after meals, with and without resulting hypoglycaemia, 
is likely to increase hunger and hence increase food intake.28,29 Moreover, it may 
stimulate the secretion of counter-regulatory hormones to restore euglycaemia.28 As a 
consequence, delayed hyperinsulinaemia may result in weight gain and worsen 
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glycaemic control. In the present study, treatment with insulin aspart exacerbated 
delayed hyperinsulinaemia, especially in patients with tmax values ≥120 min. Therefore, 
it is possible that these patients are susceptible to the adverse effects of insulin aspart. 
Our results demonstrate that treatment with insulin aspart affects not only glucose 
concentrations but also glucagon concentrations in the postprandial state. Postprandial 
hyperglucagonaemia and the consequent decreased suppression of hepatic glucose 
output are thought to contribute to postprandial hyperglycaemia.30,31 Specifically, 
suppression of plasma glucagon concentrations after glucose ingestion is weak in 
subjects with impaired glucose tolerance31 and type 2 diabetes32 as compared with 
normal subjects. In the present study, the loading of a test meal, which contains 
glucagon secretion-stimulating amino acids,33 appeared to increase glucagon 
concentrations, even in non-diabetic subjects (Fig. 3b). Although postprandial 
hyperglucagonaemia may be attributable to the reduced action of insulin on pancreatic α 
cells,30,33 insulin aspart significantly affected the value of only tmax, and not the values of 
Cmax and AUC0-180 for glucagon in the present study. Therefore, whether the effect of 
insulin aspart on glucagon secretion contributes to its hypoglycaemic action remains 
unclear and needs to be determined in future studies. 
Similar to postprandial hyperglycaemia, postprandial hyperlipidaemia is a potential 
risk factor for the development of cardiovascular disease.34 Notably, cholesterol-rich 
remnant-like lipoproteins, whose levels are increased in hypertriglyceridaemia, are 
thought to be atherogenic factors.34 It has been demonstrated that both insulin aspart35 
and insulin lispro36 have more favourable effects than human insulin on postprandial 
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hypertriglyceridaemia. Our results confirm the beneficial effect of insulin aspart on 
postprandial hypertriglyceridaemia and further show its impact on postprandial 
RLP-cholesterol accumulation. 
In summary, the rapid action and favourable pharmacodynamic properties of 
insulin aspart were preserved in patients with type 2 diabetes, even under clinical 
conditions. However, the tmax for this insulin analogue differed greatly among 
individuals. Moreover, delayed hyperinsulinaemia was exacerbated, particularly in 
patients with higher tmax values. Therefore, to improve the efficacy and safety of insulin 
aspart in the treatment of patients with type 2 diabetes, the factors responsible for 
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Table 1  Characteristics of the subjects 
 Non-diabetic subjects Patients with type 2 
diabetes 
n 5 20 
Age (years) 35 ± 7 60 ± 11 ** 
Men 3 (60) 14 (70) 
Body mass index (kg/m2) 20.7 ± 2.2 24.0 ± 2.5 * 
Fasting plasma glucose 
(mmol/l) 
5.3 ± 0.3 7.6 ± 1.2 ** 
Fasting insulin (pmol/l) 34 (29.5) 40 (50.2) 
Hemoglobin A1c (%) 5.3 ± 0.1 6.7 ± 0.5 ** 
Data are n, n (%), means ± SD, or geometric mean (geometric CV%). 











With insulin aspart 
Serum total insulin 
  Cmax (pmol/l) 246 (36.4) 245 (57.1) 505 (57.3) †** 
  tmax (min) 30, (30, 30) 60, (60, 120) †† 60 (53, 60) 
  AUC0-180 (nmol·min/l) 22.4 (47.8) 29.5 (58.0) 57.8 (62.3) ††** 
Serum endogenous insulin 
  Cmax (pmol/l) 246 (36.4) 245 (57.1) 183 (61.4) 
  tmax (min) 30, (30, 30) 60, (60, 120) †† 60, (60, 60) † 
  AUC0-180 (nmol·min/l) 22.4 (47.8) 29.5 (58.0) 21.0 (65.6) 
Plasma glucose 
  Cmax (mmol/l) 6.7 (22.6) 13.7 (14.5) †† 10.9 (13.1) ††** 
  tmax (min) 30, (30, 60) 60, (60, 120) 60, (30, 60) * 
  AUC0-180 
(mmol·min/l) 
988 (13.7) 2086 (14.9) †† 1549 (15.5) ††** 
Plasma glucagon 
  Cmax (ng/l) 130 (27.0) 139 (24.7) 129 (27.2) 
  tmax (min) 60, (30, 60) 30, (30, 60) 90, (53, 120) * 
  AUC0-180 (μg·min/l) 20.5 (26.9) 20.9 (25.1) 21.1 (25.0) 
Serum triglycerides 
  Cmax (mmol/l) 1.05 (29.4) 1.64 (30.0) † 1.55 (28.5) † 
  tmax (min) 120, (120, 120) 120, (120, 180) 120, (60, 135) 
  AUC0-180 
(mmol·min/l) 
162 (37.1) 256 (28.9) †† 235 (28.0) † 
Serum RLP-cholesterol 
  Cmax (mmol/l) 0.121 (26.8) 0.172 (29.6) 0.149 (31.5) 
  tmax (min) 120, (90, 120) 120, (83, 180) 120, (60, 180) 
  AUC0-180 
(mmol·min/l) 
18.0 (38.7) 25.9 (29.9) 22.4 (28.0) 
Cmax, maximum concentration; tmax, time to maximum concentration; AUC0-180, area under 
the concentration-time curve between 0 and 180 min after meal loading; RLP, remnant-like 
particle. 
Data are geometric mean (geometric CV%) or median (lower and upper quartiles). 
†P < 0.05, ††P < 0.01 vs. non-diabetic subjects. 
*P < 0.05, **P < 0.01 vs. diabetic patients in the trial without insulin aspart. 





Concentration-time profiles for insulin aspart and endogenous insulin after ingestion of 
a test meal. After an overnight fast, 20 patients with type 2 diabetes (white circles) and 
five non-diabetic subjects (white triangles) underwent a meal tolerance test without 
administration of insulin aspart (dashed lines). The same diabetic patients underwent 
another test in which insulin aspart was administered subcutaneously just before meal 
loading (solid lines). The mean dosage of insulin aspart was 7.0 U (range, 3–12 U). 
Data represent the means ± SE. White squares, insulin aspart plus endogenous insulin; 
black squares, insulin aspart; black circles, endogenous insulin. *P < 0.05 vs. all the 
other concentration-time profiles (repeated measures ANOVA with Bonferroni post-hoc 
tests; ten comparisons). 
 
Figure 2 
Relationships between the pharmacokinetic parameters of insulin aspart and drug dose 




Concentration-time profiles for circulating glucose (a), glucagon (b), triglycerides (c), 
and RLP-cholesterol (d) after ingestion of a test meal. After an overnight fast, 20 
patients with type 2 diabetes (white circles) and five non-diabetic subjects (white 
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triangles) underwent a meal tolerance test without administration of insulin aspart 
(dashed lines). The same diabetic patients underwent another test in which insulin aspart 
was administered subcutaneously just before meal loading (black circles and solid lines). 
Data represent the means ± SE. *P < 0.05, **P < 0.01 (repeated measures ANOVA 
with Bonferroni post-hoc test; three comparisons). 
 





